Clinical trial · Observational
MEtatastic Renal Carcinoma LINes
Pronostic Assessment of Mortality Among Locally Advanced or Metastatic Renal Cell Carcinoma Patients After First Line Treatment : Multicenter Prospective Cohort Study With Historic Medical Data
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The hypothesis of this study are as follows: * Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals. * In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities. * The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival after the first line of treatment
- timeFrame
- year 11
- description
- Time elapsed between initiation date for 2nd line treatment et the date of death, whatever the cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. Patients with locally advanced or metastatic renal cell carcinoma 2. Whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor; 3. Whatever was the overall ECOG-PS score (Eastern Cooperative Oncology Group Performance Status) at treatment initiation time 4. With first-line treatment carried out between 2007 and June 2016. Exclusion criteria: 1. Patient previously treated with only one cytokine (Interferon α2a, high-dose interleukin-2) 2. Refusal of processing of personal data
References
Publications (0)
Data not yet available